In the case of advanced breast cancer, a combination therapy–aromatase inhibitor or fulvestrant + cyclin-dependent kinase inhibitor CDK4/6, e.g., palbocyclib or tamoxifen/aromatase inhibitor/high dose fulvestrant, is used. This evidence concerns the gene CYP19A1 and breast carcinoma.